Thiopurine analogues inhibit papain-like protease of severe acute respiratory syndrome coronavirus.
Identifieur interne : 001C00 ( PubMed/Corpus ); précédent : 001B99; suivant : 001C01Thiopurine analogues inhibit papain-like protease of severe acute respiratory syndrome coronavirus.
Auteurs : Chi-Yuan Chou ; Chia-Hui Chien ; Yu-San Han ; Mojca Trstenjak Prebanda ; Hsing-Pang Hsieh ; Boris Turk ; Gu-Gang Chang ; Xin ChenSource :
- Biochemical pharmacology [ 1873-2968 ] ; 2008.
English descriptors
- KwdEn :
- MESH :
- chemical , antagonists & inhibitors : Viral Proteins.
- chemical , chemistry : Cysteine Endopeptidases, Mercaptopurine, Protease Inhibitors, Thioguanine, Viral Proteins.
- enzymology : SARS Virus.
Abstract
The papain-like protease of severe acute respiratory syndrome coronavirus (PLpro) (EC 3.4.22.46) is essential for the viral life cycle and therefore represents an important antiviral target. We have identified 6MP and 6TG as reversible and slow-binding inhibitors of SARS-CoV PLpro, which is the first report about small molecule reversible inhibitors of PLpro. The inhibition mechanism was investigated by kinetic measurements and computer docking. Both compounds are competitive, selective, and reversible inhibitors of the PLpro with K(is) values approximately 10 to 20 microM. A structure-function relationship study has identified the thiocarbonyl moiety of 6MP or 6TG as the active pharmacophore essential for these inhibitions, which has not been reported before. The inhibition is selective because these compounds do not exert significant inhibitory effects against other cysteine proteases, including SARS-CoV 3CLpro and several cathepsins. Thus, our results present the first potential chemical leads against SARS-CoV PLpro, which might be used as lead compounds for further optimization to enhance their potency against SARS-CoV. Both 6MP and 6TG are still used extensively in clinics, especially for children with acute lymphoblastic or myeloblastic leukemia. In light of the possible inhibition against subset of cysteine proteases, our study has emphasized the importance to study in depth these drug actions in vivo.
DOI: 10.1016/j.bcp.2008.01.005
PubMed: 18313035
Links to Exploration step
pubmed:18313035Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Thiopurine analogues inhibit papain-like protease of severe acute respiratory syndrome coronavirus.</title>
<author><name sortKey="Chou, Chi Yuan" sort="Chou, Chi Yuan" uniqKey="Chou C" first="Chi-Yuan" last="Chou">Chi-Yuan Chou</name>
<affiliation><nlm:affiliation>Department of Life Sciences and Institute of Genome Sciences, National Yang-Ming University, Taipei 112, Taiwan, ROC.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Chien, Chia Hui" sort="Chien, Chia Hui" uniqKey="Chien C" first="Chia-Hui" last="Chien">Chia-Hui Chien</name>
</author>
<author><name sortKey="Han, Yu San" sort="Han, Yu San" uniqKey="Han Y" first="Yu-San" last="Han">Yu-San Han</name>
</author>
<author><name sortKey="Prebanda, Mojca Trstenjak" sort="Prebanda, Mojca Trstenjak" uniqKey="Prebanda M" first="Mojca Trstenjak" last="Prebanda">Mojca Trstenjak Prebanda</name>
</author>
<author><name sortKey="Hsieh, Hsing Pang" sort="Hsieh, Hsing Pang" uniqKey="Hsieh H" first="Hsing-Pang" last="Hsieh">Hsing-Pang Hsieh</name>
</author>
<author><name sortKey="Turk, Boris" sort="Turk, Boris" uniqKey="Turk B" first="Boris" last="Turk">Boris Turk</name>
</author>
<author><name sortKey="Chang, Gu Gang" sort="Chang, Gu Gang" uniqKey="Chang G" first="Gu-Gang" last="Chang">Gu-Gang Chang</name>
</author>
<author><name sortKey="Chen, Xin" sort="Chen, Xin" uniqKey="Chen X" first="Xin" last="Chen">Xin Chen</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2008">2008</date>
<idno type="RBID">pubmed:18313035</idno>
<idno type="pmid">18313035</idno>
<idno type="doi">10.1016/j.bcp.2008.01.005</idno>
<idno type="wicri:Area/PubMed/Corpus">001C00</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001C00</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Thiopurine analogues inhibit papain-like protease of severe acute respiratory syndrome coronavirus.</title>
<author><name sortKey="Chou, Chi Yuan" sort="Chou, Chi Yuan" uniqKey="Chou C" first="Chi-Yuan" last="Chou">Chi-Yuan Chou</name>
<affiliation><nlm:affiliation>Department of Life Sciences and Institute of Genome Sciences, National Yang-Ming University, Taipei 112, Taiwan, ROC.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Chien, Chia Hui" sort="Chien, Chia Hui" uniqKey="Chien C" first="Chia-Hui" last="Chien">Chia-Hui Chien</name>
</author>
<author><name sortKey="Han, Yu San" sort="Han, Yu San" uniqKey="Han Y" first="Yu-San" last="Han">Yu-San Han</name>
</author>
<author><name sortKey="Prebanda, Mojca Trstenjak" sort="Prebanda, Mojca Trstenjak" uniqKey="Prebanda M" first="Mojca Trstenjak" last="Prebanda">Mojca Trstenjak Prebanda</name>
</author>
<author><name sortKey="Hsieh, Hsing Pang" sort="Hsieh, Hsing Pang" uniqKey="Hsieh H" first="Hsing-Pang" last="Hsieh">Hsing-Pang Hsieh</name>
</author>
<author><name sortKey="Turk, Boris" sort="Turk, Boris" uniqKey="Turk B" first="Boris" last="Turk">Boris Turk</name>
</author>
<author><name sortKey="Chang, Gu Gang" sort="Chang, Gu Gang" uniqKey="Chang G" first="Gu-Gang" last="Chang">Gu-Gang Chang</name>
</author>
<author><name sortKey="Chen, Xin" sort="Chen, Xin" uniqKey="Chen X" first="Xin" last="Chen">Xin Chen</name>
</author>
</analytic>
<series><title level="j">Biochemical pharmacology</title>
<idno type="eISSN">1873-2968</idno>
<imprint><date when="2008" type="published">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cysteine Endopeptidases (chemistry)</term>
<term>Mercaptopurine (chemistry)</term>
<term>Protease Inhibitors (chemistry)</term>
<term>SARS Virus (enzymology)</term>
<term>Thioguanine (chemistry)</term>
<term>Viral Proteins (antagonists & inhibitors)</term>
<term>Viral Proteins (chemistry)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Viral Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Cysteine Endopeptidases</term>
<term>Mercaptopurine</term>
<term>Protease Inhibitors</term>
<term>Thioguanine</term>
<term>Viral Proteins</term>
</keywords>
<keywords scheme="MESH" qualifier="enzymology" xml:lang="en"><term>SARS Virus</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The papain-like protease of severe acute respiratory syndrome coronavirus (PLpro) (EC 3.4.22.46) is essential for the viral life cycle and therefore represents an important antiviral target. We have identified 6MP and 6TG as reversible and slow-binding inhibitors of SARS-CoV PLpro, which is the first report about small molecule reversible inhibitors of PLpro. The inhibition mechanism was investigated by kinetic measurements and computer docking. Both compounds are competitive, selective, and reversible inhibitors of the PLpro with K(is) values approximately 10 to 20 microM. A structure-function relationship study has identified the thiocarbonyl moiety of 6MP or 6TG as the active pharmacophore essential for these inhibitions, which has not been reported before. The inhibition is selective because these compounds do not exert significant inhibitory effects against other cysteine proteases, including SARS-CoV 3CLpro and several cathepsins. Thus, our results present the first potential chemical leads against SARS-CoV PLpro, which might be used as lead compounds for further optimization to enhance their potency against SARS-CoV. Both 6MP and 6TG are still used extensively in clinics, especially for children with acute lymphoblastic or myeloblastic leukemia. In light of the possible inhibition against subset of cysteine proteases, our study has emphasized the importance to study in depth these drug actions in vivo.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18313035</PMID>
<DateCompleted><Year>2008</Year>
<Month>04</Month>
<Day>22</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>07</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2968</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>75</Volume>
<Issue>8</Issue>
<PubDate><Year>2008</Year>
<Month>Apr</Month>
<Day>15</Day>
</PubDate>
</JournalIssue>
<Title>Biochemical pharmacology</Title>
<ISOAbbreviation>Biochem. Pharmacol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Thiopurine analogues inhibit papain-like protease of severe acute respiratory syndrome coronavirus.</ArticleTitle>
<Pagination><MedlinePgn>1601-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bcp.2008.01.005</ELocationID>
<Abstract><AbstractText>The papain-like protease of severe acute respiratory syndrome coronavirus (PLpro) (EC 3.4.22.46) is essential for the viral life cycle and therefore represents an important antiviral target. We have identified 6MP and 6TG as reversible and slow-binding inhibitors of SARS-CoV PLpro, which is the first report about small molecule reversible inhibitors of PLpro. The inhibition mechanism was investigated by kinetic measurements and computer docking. Both compounds are competitive, selective, and reversible inhibitors of the PLpro with K(is) values approximately 10 to 20 microM. A structure-function relationship study has identified the thiocarbonyl moiety of 6MP or 6TG as the active pharmacophore essential for these inhibitions, which has not been reported before. The inhibition is selective because these compounds do not exert significant inhibitory effects against other cysteine proteases, including SARS-CoV 3CLpro and several cathepsins. Thus, our results present the first potential chemical leads against SARS-CoV PLpro, which might be used as lead compounds for further optimization to enhance their potency against SARS-CoV. Both 6MP and 6TG are still used extensively in clinics, especially for children with acute lymphoblastic or myeloblastic leukemia. In light of the possible inhibition against subset of cysteine proteases, our study has emphasized the importance to study in depth these drug actions in vivo.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chou</LastName>
<ForeName>Chi-Yuan</ForeName>
<Initials>CY</Initials>
<AffiliationInfo><Affiliation>Department of Life Sciences and Institute of Genome Sciences, National Yang-Ming University, Taipei 112, Taiwan, ROC.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Chien</LastName>
<ForeName>Chia-Hui</ForeName>
<Initials>CH</Initials>
</Author>
<Author ValidYN="Y"><LastName>Han</LastName>
<ForeName>Yu-San</ForeName>
<Initials>YS</Initials>
</Author>
<Author ValidYN="Y"><LastName>Prebanda</LastName>
<ForeName>Mojca Trstenjak</ForeName>
<Initials>MT</Initials>
</Author>
<Author ValidYN="Y"><LastName>Hsieh</LastName>
<ForeName>Hsing-Pang</ForeName>
<Initials>HP</Initials>
</Author>
<Author ValidYN="Y"><LastName>Turk</LastName>
<ForeName>Boris</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y"><LastName>Chang</LastName>
<ForeName>Gu-Gang</ForeName>
<Initials>GG</Initials>
</Author>
<Author ValidYN="Y"><LastName>Chen</LastName>
<ForeName>Xin</ForeName>
<Initials>X</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2008</Year>
<Month>01</Month>
<Day>19</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Biochem Pharmacol</MedlineTA>
<NlmUniqueID>0101032</NlmUniqueID>
<ISSNLinking>0006-2952</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011480">Protease Inhibitors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014764">Viral Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>E7WED276I5</RegistryNumber>
<NameOfSubstance UI="D015122">Mercaptopurine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber>
<NameOfSubstance UI="C099456">3C-like proteinase, Coronavirus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber>
<NameOfSubstance UI="D003546">Cysteine Endopeptidases</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>FTK8U1GZNX</RegistryNumber>
<NameOfSubstance UI="D013866">Thioguanine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D003546" MajorTopicYN="N">Cysteine Endopeptidases</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015122" MajorTopicYN="N">Mercaptopurine</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011480" MajorTopicYN="N">Protease Inhibitors</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName>
<QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013866" MajorTopicYN="N">Thioguanine</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014764" MajorTopicYN="N">Viral Proteins</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year>
<Month>11</Month>
<Day>06</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2008</Year>
<Month>01</Month>
<Day>04</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2008</Year>
<Month>01</Month>
<Day>11</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2008</Year>
<Month>3</Month>
<Day>4</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2008</Year>
<Month>4</Month>
<Day>23</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2008</Year>
<Month>3</Month>
<Day>4</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">18313035</ArticleId>
<ArticleId IdType="pii">S0006-2952(08)00037-3</ArticleId>
<ArticleId IdType="doi">10.1016/j.bcp.2008.01.005</ArticleId>
<ArticleId IdType="pmc">PMC7092826</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Fed Proc. 1984 May 15;43(8):2295-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6714435</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Eur J Biochem. 1970 Jul;15(1):97-102</Citation>
<ArticleIdList><ArticleId IdType="pubmed">5489841</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nature. 2003 Nov 27;426(6965):450-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14647384</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5717-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16581910</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Eur J Biochem. 1996 Mar 1;236(2):558-62</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8612629</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2004 Oct;78(20):11334-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15452254</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Cell. 2005 Dec 2;123(5):773-86</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16325574</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Biochemistry. 2004 Nov 30;43(47):14958-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15554703</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Antiviral Res. 2006 Nov;72(2):78-88</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16820226</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nat Rev Drug Discov. 2002 Jan;1(1):13-25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12119605</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Curr Top Microbiol Immunol. 1995;199 ( Pt 1):227-35</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7555056</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Chem Biol. 2004 Sep;11(9):1293-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15380189</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Cell. 2002 Dec 27;111(7):1041-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12507430</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Rev Med Virol. 2006 Mar-Apr;16(2):117-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16518829</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nat Med. 2004 Dec;10(12):1374-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15531891</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Curr Opin Struct Biol. 2005 Dec;15(6):664-72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16263266</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Chem Biol. 2005 Mar;12(3):303-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15797214</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virus Res. 2008 Apr;133(1):20-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17499378</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 1987 Apr;84(7):1829-33</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3031653</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>FEBS Lett. 1999 Oct 15;459(3):358-62</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10526165</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>N Engl J Med. 1998 Aug 27;339(9):605-15</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9718381</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Antiviral Res. 2005 Feb;65(2):69-78</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15708633</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2004 Aug 6;320(4):1199-203</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15249217</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nat Rev Drug Discov. 2006 Sep;5(9):785-99</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16955069</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>PLoS Med. 2006 Sep;3(9):e343</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16968120</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2002 Jun;76(12):6323-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12021365</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Lancet. 1990 Jul 28;336(8709):225-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1973780</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>EMBO J. 2005 Nov 2;24(21):3747-56</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16211010</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2005 Aug 16;102(33):11876-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16081529</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Adv Enzymol Relat Areas Mol Biol. 1988;61:201-301</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3281418</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Ann Intern Med. 1997 Apr 15;126(8):608-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9103127</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Curr Med Chem. 2006;13(17):2003-20</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16842194</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Pharmacol Exp Ther. 1981 Sep;218(3):629-35</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7196448</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nat Rev Drug Discov. 2005 Dec;4(12):1005-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16341065</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2005 Dec;79(24):15189-98</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16306590</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>PLoS Pathog. 2007 Jan;3(1):e5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17222058</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Biol Chem. 1986 Aug 5;261(22):10210-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3015923</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Biochemistry. 2005 Aug 2;44(30):10349-59</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16042412</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Biol Chem. 1993 Apr 5;268(10):7323-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8463267</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Science. 1989 Apr 7;244(4900):41-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2649979</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Pharmacol Exp Ther. 1981 Sep;218(3):621-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7196447</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nat Med. 2004 Dec;10(12 Suppl):S88-97</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15577937</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Methods. 2004 Feb;32(2):199-206</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14698633</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Antivir Chem Chemother. 2004 Jan;15(1):15-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15074711</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Pediatr. 1991 Dec;119(6):985-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1960624</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2005 Dec;79(24):15199-208</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16306591</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001C00 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001C00 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:18313035 |texte= Thiopurine analogues inhibit papain-like protease of severe acute respiratory syndrome coronavirus. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:18313035" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a SrasV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |